BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 25511804)

  • 1. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
    Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
    Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged dopamine D
    Luis-Ravelo D; Fumagallo-Reading F; Castro-Hernandez J; Barroso-Chinea P; Afonso-Oramas D; Febles-Casquero A; Cruz-Muros I; Salas-Hernandez J; Mesa-Infante V; Rodriguez-Nuñez J; Gonzalez-Hernandez T
    Pharmacol Res; 2021 Mar; 165():105434. PubMed ID: 33484816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine transporter is downregulated and its association with chaperone protein Hsc70 is enhanced by activation of dopamine D
    Chang PK; Chien KY; Chen JC
    Brain Res Bull; 2020 Dec; 165():263-271. PubMed ID: 33049353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens.
    Salles MJ; Hervé D; Rivet JM; Longueville S; Millan MJ; Girault JA; Mannoury la Cour C
    J Neurochem; 2013 May; 125(4):532-44. PubMed ID: 23410496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice.
    Le Foll B; Diaz J; Sokoloff P
    Life Sci; 2005 Jan; 76(11):1281-96. PubMed ID: 15642598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system.
    Barroso-Chinea P; Cruz-Muros I; Afonso-Oramas D; Castro-Hernández J; Salas-Hernández J; Chtarto A; Luis-Ravelo D; Humbert-Claude M; Tenenbaum L; González-Hernández T
    Neurobiol Dis; 2016 Apr; 88():44-54. PubMed ID: 26777664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons.
    Bono F; Savoia P; Guglielmi A; Gennarelli M; Piovani G; Sigala S; Leo D; Espinoza S; Gainetdinov RR; Devoto P; Spano P; Missale C; Fiorentini C
    Mol Neurobiol; 2018 Feb; 55(2):1054-1067. PubMed ID: 28092083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D3 autoreceptor inhibition enhances cocaine potency at the dopamine transporter.
    McGinnis MM; Siciliano CA; Jones SR
    J Neurochem; 2016 Sep; 138(6):821-9. PubMed ID: 27393374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
    Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter.
    Ghisi V; Ramsey AJ; Masri B; Gainetdinov RR; Caron MG; Salahpour A
    Cell Signal; 2009 Jan; 21(1):87-94. PubMed ID: 18929645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole upregulates dopamine receptor D₂ and D₃ expression in rat striatum.
    Tokunaga N; Choudhury ME; Nishikawa N; Nagai M; Tujii T; Iwaki H; Kaneta M; Nomoto M
    J Pharmacol Sci; 2012; 120(2):133-7. PubMed ID: 22986363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
    Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
    J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
    Lao CL; Kuo YH; Hsieh YT; Chen JC
    Neurotox Res; 2013 Nov; 24(4):523-31. PubMed ID: 23820985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphetamine self-administration attenuates dopamine D2 autoreceptor function.
    Calipari ES; Sun H; Eldeeb K; Luessen DJ; Feng X; Howlett AC; Jones SR; Chen R
    Neuropsychopharmacology; 2014 Jul; 39(8):1833-42. PubMed ID: 24513972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
    González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
    J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain.
    Chernoloz O; El Mansari M; Blier P
    Neuropsychopharmacology; 2009 Feb; 34(3):651-61. PubMed ID: 18688211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.